OnKure Therapeutics (OKUR) Company Total Revenue

Symbol and logo of brand OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Inc (OKUR) gross sales levels demonstrate revenue dynamics, where the value 0.00 describes the current level. The business relies on the development of targeted inhibitors to combat solid tumors. The uniqueness of the OKI-179 molecule, which suppresses breast cancer mutations, provides high profit potential. However, a critical dependence on clinical trial results and the risk of liquidity shortages create serious financial threats.

OnKure - OKUR Company Revenue (period 10/08/2024 - 11/18/2026)

Analytical breakdowns for OnKure Therapeutics Inc

- market price and analyst price targets:
- market capitalization details:
Summary company analysis:OKUR (OnKure)
Core merchandise of OnKure Therapeutics Inc

This metric accumulates the value of all goods sold per day, reflecting the actual capital density within the asset. The trend of this metric depends directly on the frequency of operational reports and shipment volumes. Analyzing the gross sales revenue of OnKure Therapeutics Inc (OKUR) allows for an objective forecast of cash flows, excluding speculative expectations. For OnKure Therapeutics Inc (OKUR), such data confirms the commercial demand for their innovative inhibitors in the targeted oncology segment.

Competing companies

Company Revenue ONC|Revenue and Sales Volume HALO|RVMD (Revolution Medicines, Inc.) - Company Sales Revenue|Company Revenue Ascentage Pharma Corp AAPG|Company Total Sales Volume CG Oncology, Inc.|URGN - Company Revenue|Bicara Therapeutics Inc. (BCAX) - Company Sales|Personalis Inc (PSNL) - Company Revenue|ERAS - Company Gross Revenue|DCTH (Delcath Systems Inc) - Revenue and Sales Volume|Company Revenue YMAB|Revenue and Sales Volume AURA|Company Revenue CADL (Candel)|Accuray, Inc. - Company Sales|SELLAS Life Sciences Group Inc. - Company Revenue|ACTU: Company Sales|Company Total Revenue Citius Oncology Inc|HURA: Revenue and Sales Volume|TARA: Company Total Sales|FATE (fatetherapeutics.com) - Revenue and Sales Volume|Company Sales Aadi Bioscience Inc (WHWK)|Revenue and Sales Volume TCRX|CSBR - Company Total Revenue|Revenue and Sales Volume XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Company Total Revenue|OSTX: Company Sales|Company Sales Revenue RADX (Radiopharm Theranostics)|Artiva (ARTV) - Company Revenue|ANL: Company Total Sales|VERU (Veru Corporation) - Revenue and Sales Volume|Company Total Revenue Tempest Therapeutics, Inc. TPST|Revenue and Sales Volume XLO|Renovaro - Company Sales Volume|Company Revenue Mural Bio MURA|KAPA: Company Sales Volume|CytoMed Therapeutics Ltd - Revenue and Sales Volume|curis.com (CRIS) - Company Sales|Apollomics Corp (APLM) - Company Revenue|Tharimmune - Company Sales Revenue|ADVB (Advanced Biomed Corp) - Revenue and Sales Volume|Company Sales Genprex, Inc (GNPX)|Revenue and Sales Volume CLDI|SBFM: Company Annual Revenue|Revenue and Sales Volume XBIO (xeneticbio.com)|Revenue and Sales Volume Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Revenue and Sales Volume|Company Total Revenue American Oncology Network, Inc.|BGNE: Revenue and Sales Volume|Company Sales checkpointtx.com|Company Revenue Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Company Gross Revenue|Company Revenue Ikena (IKNA)|NTBL - Company Total Revenue|Company Revenue viracta.com VIRX|morphosys.com (MOR) - Company Total Revenue|NAYA Biosciences Inc - Revenue and Sales Volume|AAPGV: Company Revenue